Bull case
Picard Medical is attractive because SynCardia remains the only FDA-approved and CMS/private-reimbursed total artificial heart in the U.S., backed by over 2,100 implants and pivotal-study evidence showing 69% treatment success at 30 days, 79% survival to transplantation versus 46% for controls, and 1-year post-transplant survival of 86% in bridge-to-transplant patients. Its outlook improves further as label expansion to bridge-to-candidacy is under FDA review with a decision expected in 3Q26, while Freedom+ is also under FDA review and Unicorn testing is expected to finish in 2H26, broadening access and supporting patient mobility. The market is large and underpenetrated, with an estimated U.S. opportunity of about $1.6 billion and global artificial heart market growth to $5.95 billion by 2030, while manufacturing changes target a -4.1% gross margin at current volumes and an inflection above 120 annual units.